{"transactions":[{"id":811786,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":40416,"price":6.52,"value":263512.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811785,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-08","kind":"sale","planned":false,"acquired":false,"shares":32523,"price":6.29,"value":204569.67,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811784,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":2400,"price":6.38,"value":15312.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":32523,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":811783,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:38:36.000Z","date":"2026-04-07","kind":"sale","planned":false,"acquired":false,"shares":29319,"price":6.53,"value":191453.07,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, Genesis GP, GP V, and GP VI disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":34923,"source":{"system":"sec-edgar","filing":"0000947871-26-000421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000421/ownership.xml","form_type":"4"}},{"id":1020454,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":3500000,"price":1,"value":3500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4490254,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1020453,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-11T00:06:01.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":1500000,"price":1,"value":1500000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were purchased in an underwritten registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":9026359,"source":{"system":"sec-edgar","filing":"0000947871-25-000898","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000898/ownership.xml","form_type":"4"}},{"id":1509029,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":false,"shares":9280408,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.244,"exercise_date":"2023-05-04","expiration_date":"2033-05-04","underlying":"Common Stock","underlying_shares":9280408},"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1509028,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"sale","planned":false,"acquired":false,"shares":24344,"price":0.3812,"value":9279.9328,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 15, 2024, OrbiMed Israel Partners Limited Partnership (\"OIP\") exercised pre-funded warrants (\"Warrants\") to purchase 9,280,408 shares of the Issuer's common stock for $0.244 per share. OIP paid the exercise price on a cashless basis, resulting in the Issuer withholding 24,344 of the Warrant shares to pay the exercise price and issuing to OIP the remaining 9,256,064 shares. The shares of the Issuer's common stock withheld to pay the exercise price of the Warrants are matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), with a portion of OIP's purchase of certain derivative securities on March 15, 2024. OIP will disgorge to the Issuer the statutory \"profits\" pursuant to Section 16(b) of the Exchange Act that resulted from such transactions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13773653,"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1509027,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-20T20:39:38.000Z","date":"2024-05-15","kind":"other","planned":false,"acquired":true,"shares":9280408,"price":0.244,"value":2264419.552,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OIP. OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":13797997,"source":{"system":"sec-edgar","filing":"0000947871-24-000498","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000498/ownership.xml","form_type":"4"}},{"id":1568878,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2024-03-20T01:06:46.000Z","date":"2024-03-15","kind":"purchase","planned":false,"acquired":true,"shares":2163500,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant at any time following the Stockholder Approval, subject to the Beneficial Ownership Limitation, and expire on the 24-month anniversary of the date on which they are first exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2163500,"derivative":{"exercise_price":0.2311,"underlying":"Common Stock","underlying_shares":2163500},"source":{"system":"sec-edgar","filing":"0000947871-24-000289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000289/ownership.xml","form_type":"4"}},{"id":1568877,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series X Preferred Stock","published_at":"2024-03-20T01:06:46.000Z","date":"2024-03-15","kind":"purchase","planned":false,"acquired":true,"shares":4327,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares of the Issuer's Series X Non-Voting Convertible Preferred Stock (\"Series X Preferred Stock\") were purchased from the Issuer in a private placement. Each share of Series X Preferred Stock is automatically convertible into 1,000 shares of the Issuer's common stock at 5:00 p.m. Eastern time on the fourth business day after the date the Issuer's stockholders approve the conversion of the Series X preferred Stock into shares of the Issuer's common stock (the \"Stockholder Approval\") or at any time at the option of the holder following 5:00 p.m. Eastern time on the third business day after the date the Stockholder Approval is obtained."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The conversion of the Series X Preferred Stock into shares of the Issuer's common stock is subject to an issuance limitation that prohibits the holder from converting the shares of Series X Preferred Stock into shares of the Issuer's common stock to the extent that after giving effect to such issuance after conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 19.9% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issued upon conversion of the shares of Series X Preferred Stock (the \"Beneficial Ownership Limitation\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl L. Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4327,"derivative":{"underlying":"Common Stock","underlying_shares":4327000},"source":{"system":"sec-edgar","filing":"0000947871-24-000289","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787124000289/ownership.xml","form_type":"4"}},{"id":1669923,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1041700,"price":2.4,"value":2500080.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."}],"balance_after":1255985,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669922,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":242200,"price":2.4,"value":581280.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VI."}],"balance_after":990254,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1669921,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-27T00:14:22.000Z","date":"2024-01-25","kind":"purchase","planned":false,"acquired":true,"shares":1841100,"price":2.4,"value":4418640.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis GP, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":7526359,"source":{"system":"sec-edgar","filing":"0000950170-24-008053","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000095017024008053/ownership.xml","form_type":"4"}},{"id":1842241,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":58000,"price":2.09,"value":121220.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VI and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":748054,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842240,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":442000,"price":2.09,"value":923780.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI V and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5685259,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842239,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":2.09,"value":522500.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power over the shares of common stock held by OIP II and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel II exercises this investment and voting power through an investment committee comprised of Carl L. Gordon, David Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":646657,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1842238,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":9,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T20:46:01.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":2.09,"value":261250.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of common stock purchased, ranging from a low of $2.08 to a high of $2.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power over the shares of common stock held by OIP and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Israel GP exercises this investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership over the shares of common stock held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, OrbiMed Israel II, GP V, GP VI, Genesis GP, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his or its pecuniary interest therein, if any. OrbiMed Advisors, GP V and GP VI have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1027885,"source":{"system":"sec-edgar","filing":"0000947871-23-000713","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787123000713/ownership.xml","form_type":"4"}},{"id":1947120,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-03-17T20:29:56.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":1789959,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1789959,"derivative":{"exercise_price":0.244,"exercise_date":"2023-02-27","expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":1789959},"source":{"system":"sec-edgar","filing":"0000947871-23-000336","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787123000336/ownership.xml","form_type":"4"}},{"id":1947119,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24161,"kind":"person","name":"GORDON CARL L","position":3,"cik":"0001282930","reported_name":"GORDON CARL L","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24622,"kind":"person","name":"Chimovits Erez","position":4,"cik":"0001706399","reported_name":"Chimovits Erez","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-03-17T20:29:56.000Z","date":"2023-02-27","kind":"purchase","acquired":true,"shares":348000,"price":0.245,"value":85260.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3161489,"source":{"system":"sec-edgar","filing":"0000947871-23-000336","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706399/000094787123000336/ownership.xml","form_type":"4"}},{"id":2061808,"issuer":{"id":7653,"kind":"organization","name":"Chemomab Therapeutics Ltd."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depository Shares","published_at":"2023-01-05T21:49:08.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":70524,"price":4.51,"value":318063.24,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each American Depository Share (\"ADS\") represents 20 Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the ADSs sold, ranging from a low of $3.87 to a high of $4.83 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These ADSs are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2241274,"source":{"system":"sec-edgar","filing":"0000947871-23-000015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000094787123000015/ownership.xml","form_type":"4"}},{"id":2061807,"issuer":{"id":7653,"kind":"organization","name":"Chemomab Therapeutics Ltd."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depository Shares","published_at":"2023-01-05T21:49:08.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":266376,"price":3.34,"value":889695.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each American Depository Share (\"ADS\") represents 20 Ordinary Shares of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the ADSs sold, ranging from a low of $2.85 to a high of $3.81 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These ADSs are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2311798,"source":{"system":"sec-edgar","filing":"0000947871-23-000015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000094787123000015/ownership.xml","form_type":"4"}},{"id":2474025,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":5,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":6,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":7,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":8,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-14T23:41:26.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":214285,"price":14,"value":2999990.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares of the Issuer's common stock are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, Genesis, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund, and OrbiMed Israel GP have designated Carl L. Gordon (\"Gordon\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Gordon is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":242285,"source":{"system":"sec-edgar","filing":"0000947871-21-001280","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121001280/ownership.xml","form_type":"4"}},{"id":2620993,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2021-07-30T22:20:35.000Z","date":"2021-07-28","kind":"purchase","acquired":true,"shares":375000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership (\"OIP\") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock.  The purchase price of each unit was $4.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership (\"OIP\") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock.  The purchase price of each unit was $4.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchase reported on this Form 4 were made by OIP.  Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":375000,"derivative":{"exercise_price":5,"exercise_date":"2022-01-28","expiration_date":"2027-01-28","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0000947871-21-000844","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787121000844/ownership.xml","form_type":"4"}},{"id":2620992,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-07-30T22:20:35.000Z","date":"2021-07-28","kind":"purchase","acquired":true,"shares":500000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership (\"OIP\") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock.  The purchase price of each unit was $4.00."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership (\"OIP\") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock.  The purchase price of each unit was $4.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership (\"OIP\") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock.  The purchase price of each unit was $4.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchase reported on this Form 4 were made by OIP.  Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2813489,"source":{"system":"sec-edgar","filing":"0000947871-21-000844","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787121000844/ownership.xml","form_type":"4"}},{"id":2654456,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T19:08:22.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":15989876,"price":1.21,"value":19347749.96,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":8565974,"source":{"system":"sec-edgar","filing":"0000947871-21-000712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000712/ownership.xml","form_type":"4"}},{"id":2654455,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T19:08:22.000Z","date":"2021-06-24","kind":"sale","acquired":false,"shares":319255,"price":1.38,"value":440571.9,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":24555850,"source":{"system":"sec-edgar","filing":"0000947871-21-000712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000712/ownership.xml","form_type":"4"}},{"id":2654454,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-25T19:08:22.000Z","date":"2021-06-23","kind":"sale","acquired":false,"shares":841650,"price":1.36,"value":1144644.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":24875105,"source":{"system":"sec-edgar","filing":"0000947871-21-000712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000712/ownership.xml","form_type":"4"}},{"id":2714024,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T18:34:33.000Z","date":"2021-05-11","kind":"other","acquired":true,"shares":19444,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted to Darvish on July 6, 2020 and vests in 36 monthly installments beginning July 6, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This option was granted to Darvish on July 6, 2020 and vests in 36 monthly installments beginning July 6, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP."}],"balance_after":80556,"derivative":{"exercise_price":0.6216,"expiration_date":"2030-07-06","underlying":"Common Stock","underlying_shares":19444},"source":{"system":"sec-edgar","filing":"0000947871-21-000520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000520/ownership.xml","form_type":"4"}},{"id":2714023,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-13T18:34:33.000Z","date":"2021-05-11","kind":"other","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted to Darvish on April 30, 2020 and vests in 36 monthly installments beginning April 30, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This option was granted to Darvish on April 30, 2020 and vests in 36 monthly installments beginning April 30, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP."}],"balance_after":37500,"derivative":{"exercise_price":0.7,"expiration_date":"2030-04-30","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000947871-21-000520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000520/ownership.xml","form_type":"4"}},{"id":2714022,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T18:34:33.000Z","date":"2021-05-11","kind":"other","acquired":true,"shares":19444,"price":0.6216,"value":12086.3904,"ownership":{"direct":false,"nature":"See Footnotes (1)(2"},"balance_after":25748699,"source":{"system":"sec-edgar","filing":"0000947871-21-000520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000520/ownership.xml","form_type":"4"}},{"id":2714021,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T18:34:33.000Z","date":"2021-05-11","kind":"other","acquired":true,"shares":12500,"price":0.7,"value":8750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock are held of record by Nissim Darvish (\"Darvish\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OrbiMed Israel Partners Limited Partnership (\"OIP\"), and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25729255,"source":{"system":"sec-edgar","filing":"0000947871-21-000520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000520/ownership.xml","form_type":"4"}},{"id":2777268,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-03-19T18:00:28.000Z","date":"2020-05-04","kind":"purchase","acquired":true,"shares":67865,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6786500,"derivative":{"exercise_date":"2020-05-04","expiration_date":"2025-05-04","underlying":"Common Stock","underlying_shares":6786500},"source":{"system":"sec-edgar","filing":"0000947871-21-000352","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000352/ownership.xml","form_type":"4/A","original_submission_date":"2020-05-04"}},{"id":2777267,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-03-19T18:00:28.000Z","date":"2020-05-04","kind":"purchase","acquired":true,"shares":67865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":6786500,"derivative":{"exercise_date":"2020-05-04","underlying":"Common Stock","underlying_shares":6786500},"source":{"system":"sec-edgar","filing":"0000947871-21-000352","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000352/ownership.xml","form_type":"4/A","original_submission_date":"2020-05-04"}},{"id":2777266,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-19T18:00:28.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":18930255,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Received in exchange for shares of RDD Pharma Ltd. in connection with the in the merger of RDD Pharma Ltd. into a wholly-owned subsidiary of the Issuer in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of October 6, 2019, as amended on December 17, 2019 (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for shares of RDD Pharma Ltd. in connection with the in the merger of RDD Pharma Ltd. into a wholly-owned subsidiary of the Issuer in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of October 6, 2019, as amended on December 17, 2019 (the \"Merger\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":18930255,"source":{"system":"sec-edgar","filing":"0000947871-21-000352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000094787121000352/ownership.xml","form_type":"4/A","original_submission_date":"2020-05-04"}},{"id":2778755,"issuer":{"id":7653,"kind":"organization","name":"Chemomab Therapeutics Ltd."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2021-03-19T01:59:48.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":28817,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The warrants are held of record by OIP and are immediately exercisable."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The warrants are held of record by OIP and are immediately exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrants are held of record by OIP and are immediately exercisable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":28817,"derivative":{"exercise_price":17.35,"expiration_date":"2026-03-16","underlying":"American Depository Shares","underlying_shares":28817},"source":{"system":"sec-edgar","filing":"0000947871-21-000350","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000094787121000350/ownership.xml","form_type":"4"}},{"id":2778754,"issuer":{"id":7653,"kind":"organization","name":"Chemomab Therapeutics Ltd."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depository Shares","published_at":"2021-03-19T01:59:48.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":288170,"price":17.35,"value":4999749.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each ADS represents twenty (20) Ordinary Shares of the Issuer. These ADSs were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2578174,"source":{"system":"sec-edgar","filing":"0000947871-21-000350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000094787121000350/ownership.xml","form_type":"4"}},{"id":2851473,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":104050,"price":13,"value":1352650.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":396657,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2851472,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T02:38:27.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":420299,"price":13,"value":5463887.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of the Issuer's common stock were purchased in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"This report is being jointly filed by OrbiMed Advisors, GP V, GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5243259,"source":{"system":"sec-edgar","filing":"0000947871-21-000240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787121000240/ownership.xml","form_type":"4"}},{"id":2956470,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-04T22:17:51.000Z","date":"2020-12-02","kind":"sale","acquired":false,"shares":103200,"price":21.6,"value":2229120.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":73650,"source":{"system":"sec-edgar","filing":"0000947871-20-000933","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787120000933/ownership.xml","form_type":"4"}},{"id":2994223,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-11-03T16:14:48.000Z","date":"2020-10-30","kind":"other","acquired":true,"shares":1943734,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of common stock of the Issuer reported on this Form 4 were released from escrow pursuant to Section 1.12 of that certain Agreement and Plan of Merger and Reorganization dated as of October 6, 2019 (as amended by Amendment No. 1 thereto, dated as of December 17, 2019). The Reporting Person's right to receive such escrowed shares became fixed and irrevocable on October 30, 2020, the six-month anniversary of the closing date of the merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"). OrbiMed Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":25716755,"source":{"system":"sec-edgar","filing":"0001551986-20-000295","document":"wf-form4_160443807542838.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000295/wf-form4_160443807542838.xml","form_type":"4"}},{"id":3028958,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This option is held by Chimovits. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Chimovits remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, Chimovits is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund, OrbiMed Israel GP, OrbiMed Israel GP II, and OrbiMed Israel II, which will in turn ensure that such securities or economic benefit are provided to OIP and OIP II."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028957,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This option is held by Gordon. 1/36th of the shares of the Issuer's common stock subject to the option shall vest on each of the next thirty-six (36) monthly anniversaries of the grant date, provided that Gordon remains in continuous service as of the applicable vesting date. Pursuant to agreements with OrbiMed Advisors, GP V, and GP VI, Gordon is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors, GP V, and GP VI, which will in turn ensure that such securities or economic benefits are provided to OPI V and OPI VI."}],"balance_after":30000,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028956,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":292607,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for 2,359,734 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"OrbiMed Israel GP II\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"OrbiMed Israel II\") is the general partner of OrbiMed Israel GP II. By virtue of such relationships, OrbiMed Israel GP II and OrbiMed Israel II may be deemed to have voting and investment power with respect to the shares held directly by OIP II noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel II exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II."}],"balance_after":292607,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028955,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":902885,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for 7,281,335 shares of the common stock of Old Adicet on the closing of the Merger, as described in footnote 2."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel GP\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the shares held directly by OIP noted above and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz, and Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP."}],"balance_after":902855,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3028954,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53130,"kind":"organization","name":"OrbiMed Capital GP V LLC","position":2,"cik":"0001615374","reported_name":"OrbiMed Capital GP V LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":3,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":4,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":5,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":6,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":7,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-18T01:45:55.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":4822960,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 38,894,843 shares of the common stock of Adicet Bio, Inc., (\"Old Adicet\") on the closing of the merger (the \"Merger\") pursuant to the Agreement and Plan of Merger dated April 18, 2020 (the \"Merger Agreement\") by and among the Issuer, Old Adicet and Project Oasis Merger Sub, Inc., a direct, wholly-owned subsidiary of the Issuer, whereby each share of Old Adicet common stock was canceled and automatically converted into .1240 shares of Issuer common stock (the \"Exchange Ratio\"), with fractional shares being eliminated after first being aggregated, as provided in the Merger Agreement. The Issuer was renamed Adicet Bio, Inc. following the closing of the Merger."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares of the Issuer's common stock are held of record by OrbiMed Private Investments V, LP (\"OPI V\"). OrbiMed Capital GP V LLC (\"GP V\") is the general partner of OPI V, and OrbiMed Advisors is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI V."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report is being jointly filed by OrbiMed Advisors, OrbiMed GP V, OrbiMed GP VI, OrbiMed Israel GP II, OrbiMed Israel II, OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. The Reporting Persons have designated Carl L. Gordon (\"Gordon\") and Erez Chimovits (\"Chimovits\") to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, Gordon, or Chimovits is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4822960,"source":{"system":"sec-edgar","filing":"0000947871-20-000738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787120000738/ownership.xml","form_type":"4"}},{"id":3090850,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-07-02T16:25:21.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":67865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020."}],"balance_after":0,"derivative":{"exercise_date":"2020-05-04","underlying":"Common stock","underlying_shares":6786500},"source":{"system":"sec-edgar","filing":"0001551986-20-000206","document":"wf-form4_159372148134168.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000206/wf-form4_159372148134168.xml","form_type":"4"}},{"id":3090849,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-07-02T16:25:21.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":6786500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":23773021,"source":{"system":"sec-edgar","filing":"0001551986-20-000206","document":"wf-form4_159372148134168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000206/wf-form4_159372148134168.xml","form_type":"4"}},{"id":3160664,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Warrant","published_at":"2020-05-05T16:20:31.000Z","date":"2020-05-04","kind":"purchase","acquired":true,"shares":67865,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6786500,"derivative":{"exercise_date":"2020-05-04","expiration_date":"2025-05-04","underlying":"Common stock","underlying_shares":6786500},"source":{"system":"sec-edgar","filing":"0001551986-20-000137","document":"wf-form4_158871001437742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000137/wf-form4_158871001437742.xml","form_type":"4"}},{"id":3160663,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-05-05T16:20:31.000Z","date":"2020-05-04","kind":"purchase","acquired":true,"shares":67865,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":6786500,"derivative":{"exercise_date":"2020-05-04","underlying":"Common stock","underlying_shares":6786500},"source":{"system":"sec-edgar","filing":"0001551986-20-000137","document":"wf-form4_158871001437742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000137/wf-form4_158871001437742.xml","form_type":"4"}},{"id":3163353,"issuer":{"id":114271,"kind":"organization","name":"9 METERS BIOPHARMA, INC.","symbol":"NMTR"},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-04T19:21:26.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in 36 equal monthly installments beginning April 30, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Nissim Darvish, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":50000,"derivative":{"exercise_price":0.7,"expiration_date":"2030-04-30","underlying":"Common stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001551986-20-000127","document":"wf-form4_158863446905549.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1551986/000155198620000127/wf-form4_158863446905549.xml","form_type":"4"}},{"id":3248962,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2020-02-25T22:17:24.000Z","date":"2020-01-14","kind":"sale","acquired":true,"shares":646204,"price":0.2,"value":129240.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"derivative":{"exercise_date":"2019-05-02","expiration_date":"2024-05-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-20-000146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787120000146/ownership.xml","form_type":"4"}},{"id":3248961,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2020-02-25T22:17:24.000Z","date":"2020-01-14","kind":"sale","acquired":true,"shares":646204,"price":0.2,"value":129240.8,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"derivative":{"exercise_date":"2019-05-02","expiration_date":"2020-11-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-20-000146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787120000146/ownership.xml","form_type":"4"}},{"id":3333607,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-20T18:58:48.000Z","date":"2019-12-19","kind":"purchase","acquired":true,"shares":3500,"price":8.9,"value":31150.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2313489,"source":{"system":"sec-edgar","filing":"0000947871-19-000983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000983/ownership.xml","form_type":"4"}},{"id":3333606,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-20T18:58:48.000Z","date":"2019-12-18","kind":"purchase","acquired":true,"shares":500,"price":8.93,"value":4465.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2309989,"source":{"system":"sec-edgar","filing":"0000947871-19-000983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000983/ownership.xml","form_type":"4"}},{"id":3343397,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-12T23:52:07.000Z","date":"2019-12-11","kind":"purchase","acquired":true,"shares":5400,"price":8.92,"value":48168.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2309489,"source":{"system":"sec-edgar","filing":"0000947871-19-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000961/ownership.xml","form_type":"4"}},{"id":3343396,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-12T23:52:07.000Z","date":"2019-12-10","kind":"purchase","acquired":true,"shares":3400,"price":8.75,"value":29750.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,668,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2304089,"source":{"system":"sec-edgar","filing":"0000947871-19-000961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000961/ownership.xml","form_type":"4"}},{"id":3347781,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:30:28.000Z","date":"2019-12-09","kind":"purchase","acquired":true,"shares":6000,"price":8.68,"value":52080.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2300689,"source":{"system":"sec-edgar","filing":"0000947871-19-000948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000948/ownership.xml","form_type":"4"}},{"id":3347780,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:30:28.000Z","date":"2019-12-06","kind":"purchase","acquired":true,"shares":800,"price":8,"value":6400.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2294689,"source":{"system":"sec-edgar","filing":"0000947871-19-000948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000948/ownership.xml","form_type":"4"}},{"id":3347779,"issuer":{"id":8384,"kind":"organization","name":"Tessera Defense & Homeland Security Inc."},"owners":[{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":1,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":2,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2019-12-10T01:30:28.000Z","date":"2019-12-05","kind":"purchase","acquired":true,"shares":3400,"price":7.99,"value":27166.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a decrease of one share to account for rounding of fractional shares initially reported on the Reporting Persons' Form 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership (\"OIP LP\"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,659,350 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership (\"OII LP\") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\"), which is the general partner of each of OIP LP and OII LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of the relationships described in footnote 2, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2293889,"source":{"system":"sec-edgar","filing":"0000947871-19-000948","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1569590/000094787119000948/ownership.xml","form_type":"4"}},{"id":3537916,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2019-05-06T21:30:22.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":646204,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2024-05-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-19-000337","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787119000337/ownership.xml","form_type":"4"}},{"id":3537915,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2019-05-06T21:30:22.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Warrants (\"Warrants\") to purchase shares of the Issuer's common stock (\"Shares\"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":646204,"derivative":{"exercise_date":"2019-05-02","expiration_date":"2020-11-02","underlying":"Common Stock","underlying_shares":646204},"source":{"system":"sec-edgar","filing":"0000947871-19-000337","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787119000337/ownership.xml","form_type":"4"}},{"id":3537914,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T21:30:22.000Z","date":"2019-05-02","kind":"purchase","acquired":true,"shares":646204,"price":3.1,"value":2003232.4,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power with respect to the securities held by OIP and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes."}],"balance_after":3183314,"source":{"system":"sec-edgar","filing":"0000947871-19-000337","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000094787119000337/ownership.xml","form_type":"4"}},{"id":4324524,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":53133,"kind":"organization","name":"OrbiMed Israel GP Ltd.","position":1,"cik":"0001569590","reported_name":"OrbiMed Israel GP Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53134,"kind":"organization","name":"OrbiMed Israel BioFund GP Limited Partnership","position":2,"cik":"0001569821","reported_name":"OrbiMed Israel BioFund GP Limited Partnership","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-05-11T20:13:03.000Z","date":"2017-05-09","kind":"grant","acquired":true,"shares":2537110,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received in exchange for 3,898,632 shares of Otic Pharma, Ltd. Series B Preferred Shares, 816,954 shares of Series C Preferred Shares and 96,637 shares of Ordinary Shares in connection with the closing of the share purchase transaction with Otic Pharma, Ltd. All numbers give effect to the 9:1 reverse stock split effected by the Company on May 11, 2017 (the \"Reverse Stock Split\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 3,898,632 shares of Otic Pharma, Ltd. Series B Preferred Shares, 816,954 shares of Series C Preferred Shares and 96,637 shares of Ordinary Shares in connection with the closing of the share purchase transaction with Otic Pharma, Ltd. All numbers give effect to the 9:1 reverse stock split effected by the Company on May 11, 2017 (the \"Reverse Stock Split\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership (\"OIP\"). OrbiMed Israel BioFund GP Limited Partnership (\"OrbiMed BioFund\") is the general partner of OIP, and OrbiMed Israel GP Ltd. (\"OrbiMed Israel\") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and as a result may be deemed to have beneficial ownership over such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Erez Chimovits, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Persons, is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2537110,"source":{"system":"sec-edgar","filing":"0000899243-17-012816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924317012816/doc4.xml","form_type":"4"}}]}